ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

Starbucks Corporation SBUX gained 5.7% to $106.15 following better-than-expected quarterly financial results. Additionally, ...

Snappt, the trusted leader in fraud detection for multifamily property management, today released its 2024 Fraud Report: Data, Trends, and Strategies for 2025. The report provides insights from its ...

Sidney, a book developer and publisher, announced today the publication of YOU ARE THE DOCTOR: The Importance of a Team Approach in Cancer Treatment by the late Susan Finlay Dunbar, MD. A unique ...

DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ ...

The market remained flat over the last week but is up 23% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a ...

Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an ...

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital ...

We recently compiled a list of the These 10 Firms Dominated Last Week's Rally. In this article, we are going to take a look ...